Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 févr. 2022 11h00 HE | Source: NeuroSigma, Inc.

NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®

LOS ANGELES, Feb. 22, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced FDA Breakthrough Device Designation for its Monarch eTNS System® for...
25 janv. 2022 22h30 HE | Source: NeuroSigma, Inc.

Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction

Ignis obtains rights to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System in ChinaInitial launch of Generation 1.0 device followed by Generation 1.5 device, to deploy in mainland...
11 janv. 2022 11h00 HE | Source: NeuroSigma, Inc.

NeuroSigma Announces Promotion of Dr. Colin Kealey to President

LOS ANGELES, Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion of Dr. Colin Kealey to President. NeuroSigma is the developer...
08 déc. 2021 05h00 HE | Source: NeuroSigma, Inc.

NeuroSigma Announces a $5 Million Equity Investment by KT Corporation

Transaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KTSignificant investment in NeuroSigma’s digital health and neuro-electronics platform ...